Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b

Biochemical Pharmacology

Volumn 57, Issue 12, 1999, Pages 1439-1446

  Sahu, Arvind ^a   Rawal, Nenoo ^a   Pangburn, Michael K ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

C3; Complement; Complement inhibitors; Rosmarinic acid; Thioester

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; ROSMARINIC ACID;

ANIMAL CELL; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SHEEP ERYTHROCYTE;

ANIMALS; CINNAMATES; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C3B; COMPLEMENT C3B INACTIVATOR PROTEINS; DEPSIDES; ERYTHROCYTES; HEMOLYSIS; HUMANS; SHEEP;

EID: 0032937081     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00044-1     Document Type: Article

References (35)

1. Christ B and Kesselring K, Process for isolating rosmarinic acid from plants. US Patent 4,354.035, 1982.
2. Leyck E., Etschenberg E., Hadding U., Winkelmann J. A new model of acute inflammation Cobra venom factor induced paw oedema . Agents Actions. 13:1983;437-438.
3. Englberger W., Hadding U., Etschenberg E., Graf E., Leyck S., Winkelmann J., Parnham M.J. Rosmarinic acid A new inhibitor of complement C3 convertase with anti-inflammatory activity . Int J Immunopharmacol. 10:1988;729-737.
4. Peake P.W., Pussell B.A., Martyn P., Timmermans V., Charlesworth J.A. The inhibitory effect of rosmarinic acid on complement involves the C5 convertase. Int J Immunopharmacol. 13:1991;853-857.
5. Rampart M., Beetens J.R., Bult H., Herman A.G., Parnham M.J., Winkelmann J. Complement-dependent stimulation of prostacyclin biosynthesis Inhibition by rosmarinic acid . Biochem Pharmacol. 35:1986;1397-1400.
6. Verweij-van Vught A.M.J.J., Appelmelk B.J., Groeneveld A.B.J., Sparrius M., Thijs L.G., MacLaren D.M. Influence of rosmarinic acid on opsonization and intracellular killing of Escherichia coli and Staphylococcus aureus by porcine and human polymorphonuclear leucocytes. Agents Actions. 22:1987;288-294.
7. Ritschel W.A., Starzacher A., Sabouni A., Hussain A.S., Koch H.P. Percutaneous absorption of rosmarinic acid in the rat. Methods Find Exp Clin Pharmacol. 11:1989;345-352.
8. van Kessel K.P., Kalter E.S., Verhoef J. Rosmarinic acid inhibits external oxidative effects of human polymorphonuclear granulocytes. Agents Actions. 17:1986;375-376.
9. Sahu A., Pangburn M.K. Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3. Biochem Pharmacol. 51:1996;797-804.
10. Sahu A., Pangburn M.K. Tyrosine is a potential site for covalent attachment of activated complement component C3. Mol Immunol. 32:1995;711-716.
11. Sahu A., Kozel T.R., Pangburn M.K. Specificity of the thioester-containing site of human C3 and its significance to complement activation. Biochem J. 302:1994;429-436.
12. Hammer C.H., Wirtz G.H., Renfer L., Gresham H.D., Tack B.F. Large scale isolation of functionally active components of the human complement system. J Biol Chem. 256:1981;3995-4006.
13. Pangburn M.K. A fluorimetric assay for native C3. The hemolytically active form of the third component of human complement. J Immunol Methods. 102:1987;7-14.
14. Götze O., Müller-Eberhard H.J. The C3-activator system An alternative pathway of complement activation . J Exp Med. 134:1971;90s-108s.
15. Lesavre P.H., Hugli T.E., Esser A.F., Müller-Eberhard H.J. The alternative pathway C3/C5 convertase Chemical basis of factor B activation . J Immunol. 123:1979;529-534.
16. Vogel C.W., Müller-Eberhard H.J. The cobra venom factor-dependent C3 convertase of human complement. J Biol Chem. 257:1982;8292-8299.
17. Discipio R.G., Smith C.A., Müller-Eberhard H.J., Hugli T.E. The activation of human complement component C5 by a fluid phase C5 convertase. J Biol Chem. 258:1983;10629-10636.
18. Pangburn M.K., Müller-Eberhard H.J. Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med. 152:1980;1102-1114.
19. Sahu A., Pangburn M.K. Covalent attachment of human complement C3 to IgG Identification of the amino acid residue involved in ester linkage formation . J Biol Chem. 269:1994;28997-29002.
20. Pangburn M.K., Müller-Eberhard H.J. The C3 convertase of the alternative pathway of human complement. Enzymatic properties of the biomolecular proteinase. Biochem J. 235:1986;723-730.
21. Law S.K., Lichtenberg N.A., Levine R.P. Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol. 123:1979;1388-1394.
22. Law S.K.A., Minich T.M., Levine R.P. Binding reaction between the third human complement protein and small molecules. Biochemistry. 20:1981;7457-7463.
23. Law S.K., Minich T.M., Levine R.P. Covalent binding efficiency of the third and fourth complement proteins in relation to pH, nucleophilicity, and availability of hydroxyl groups. Biochemistry. 23:1984;3267-3272.
24. Kim Y.U., Carroll M.C., Isenman D.E., Nonaka M., Pramoonjago P., Takeda J., Inoue K., Kinoshita T. Covalent binding of C3b to C4b within the classical complement pathway C5 convertase. Determination of amino acid residues involved in ester linkage formation. J Biol Chem. 267:1992;4171-4176.
25. Kinoshita T., Takata Y., Kozono H., Takeda J., Hong K., Inoue K. C5 convertase of the alternative complement pathway Covalent linkage between two C3b molecules within the trimolecular complex enzyme . J Immunol. 141:1988;3895-3901.
26. Higgins P.J., Ko J.-L., Lobell R., Sardonini C., Alessi M.K., Yeh C.G. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. J Immunol. 158:1997;2872-2881.
27. Moore F.D. Jr. Therapeutic regulation of the complement system in acute injury states. Adv Immunol. 56:1994;267-299.
28. Weisman H.F., Bartow T., Leppo M.K., Marsh H.C., Carson G.R., Concino M.F., Boyle M.P., Roux K.H., Weisfeldt M.L., Fearon D.T. Soluble human complement receptor type 1 In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis . Science. 249:1990;146-151.
29. Wang Y., Rollins S.A., Madri J.A., Matis L.A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA. 92:1995;8955-8959.
30. Matis L.A., Rollins S.A. Complement-specific antibodies, Designing novel anti-inflammatories. Nature Med. 1:1995;839-842.
31. Sahu A., Kay B.K., Lambris J.D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol. 157:1996;884-891.
32. Glover G.I., Schasteen C.S., Liu W.-S., Levine R.P. Synthetic peptide inhibitors of complement serine proteases - I. Identification of functionally equivalent protease inhibitor sequences in serpins and inhibition of C1s and D. Mol Immunol. 25:1988;1261-1267.
33. Issekutz A.C., Roland D.M., Patrick R.A. The effect of FUT-175 (nafamstat mesilate) on C3a, C4a and C5a generation in vitro and inflammatory reactions in vivo. Int J Immunopharmacol. 12:1990;1-9.
34. 2 fragments and rosmarinic acid. Br J Pharmacol. 84:1985;317-327.
35. Nuytinck J.K.S., Goris R.J.A., Kalter E.S., Schillings P.H.M. Inhibition of experimentally induced microvascular injury by rosmarinic acid. Agents Actions. 17:1985;373-374.